FindTrial
Sign In

The correlative study between auto-antibodies against AT1-receptor, autoantibodies against alpha1-adrenergic receptor and endothelial function in patients with hypertension

The correlative study between auto-antibodies against AT1-receptor, autoantibodies against alpha1-adrenergic receptor and endothelial function in patients with hypertension

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016061
Enrollment
Unknown
Registered
2018-05-09
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

1:The treatment controlling circadian pattern
2:Placebo

Sponsors

Dongfeng General Hospital of Sinopharm
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 87 Years

Inclusion criteria

Inclusion criteria: SBP=140mmHg or DBP=90mmHg,measurement of blood pressure 3 times not on the same day ,after giving standardized hypotensive therapy.

Exclusion criteria

Exclusion criteria: secondary hypertension,acute hypertension because of drug/pain etc,adverse effects on the target organs such as the heart, the brain, the kidney, heart failure,atrial fibrillation and so on, acute infection or by corresponding treatment, coronary heart disease, diabetes,adiposity, dyslipidemia, damaged liver or kidney functions,positive urinary protein, heart valve disease, stroke, TIA, thyroid disease, cancer, fever, gout, primary kidney disease.

Design outcomes

Primary

MeasureTime frame
Circulating endothelial microparticles;flow-mediated dilation;coronary arteriongraphy;autoantibodies against AT1-receptor;autoantibody against a1-adrenoceptor;circadian blood pressure;—

Countries

China

Contacts

Public ContactZheng Cheng

Depatment of Cadiovascular Medicine, Dongfeng General Hospital of Sinopharm

13593737568@139.com+86 13593737568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026